ArticleEndocrine connections2026
LAT1-mediated amino acid metabolism reprogramming: a novel metabolic vulnerability in recurrent pituitary neuroendocrine tumors.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Tumor recurrence remains a major challenge in the management of pituitary neuroendocrine tumors (PitNETs). This study aimed to investigate recurrence-associated metabolic alterations in PitNETs using an integrated metabolomic approach. Methods: Untargeted gas chromatography-mass spectrometry (GC-MS)-based metabolomic profiling was performed on tumor tissues from 44 patients with PitNETs as a discovery cohort. Differential metabolites were identified using non-parametric statistical analysis. An independent validation cohort of 40 patients (20 primary and 20 recurrent PitNETs) was used for protein-level validation by multiplex immunofluorescence staining of key amino acid transporters, including L-type amino acid transporter 1 (LAT1) and alanine-serine-cysteine transporter 2 (ASCT2). Results: Metabolomic analysis revealed distinct metabolic alterations between primary and recurrent PitNETs, characterized by selective enrichment of large neutral amino acids (LNAAs) in recurrent tumors. Pathway enrichment analysis indicated that the altered metabolites were predominantly involved in amino acid-related metabolic pathways. In the validation cohort, multiplex immunofluorescence demonstrated significantly increased LAT1 expression in recurrent PitNETs compared with primary tumors, whereas ASCT2 expression did not differ significantly between groups. Conclusion: These findings indicate that recurrence of PitNETs is associated with selective remodeling of amino acid metabolism, particularly involving LNAAs, accompanied by increased expression of the corresponding transporter LAT1. Together, our results suggest that altered amino acid transport represents an important component of metabolic adaptation in recurrent PitNETs and warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.